Motor Neurone Disease Partnering - 2009-2014





Published: March 2014 | Pages: 100 | Format: PDF

 The Motor Neurone Disease Partnering 2009-2014 provides understanding and access to the motor neurone disease partnering deals and agreements entered into by the worlds leading healthcare companies . 

 The report provides an analysis of motor neurone disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors migraine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. 

 This data driven report contains over 50 links to online copies of actual migraine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. 

 The initial chapters of this report provide an orientation of motor neurone disease partnering trends. 

 Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in motor neurone disease partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends. 

 Chapter 3 provides an overview of the leading motor neurone disease deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. 

 Chapter 4 provides a comprehensive directory of motor neurone disease partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand. 

 In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of motor neurone disease technologies and products. 

 Report scope 

 Motor Neurone Disease Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to motor neurone disease trends and structure of deals entered into by leading companies worldwide. 

 This data driven report includes: 

 

  •  Trends in motor neurone disease dealmaking in the biopharma industry since 2009  
  •  Access to summary headline, upfront, milestone and royalty data  
  •  The leading motor neurone disease deals by value since 2009  

 

 In Motor Neurone Disease Partnering 2009-2014, the available deals are listed by: 

 

  •  Headline value  
  •  Upfront payment value  
  •  Royalty rate value  
  •  Company A-Z  
  •  Industry sector  
  •  Stage of development at signing  
  •  Deal component type  
  •  Technology type  

 

 Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

 Motor Neurone Disease Partnering 2009-2014 provides the reader with the following key benefits: 

 

  •  In-depth understanding of motor neurone disease deal trends since 2009  
  •  Access to summary headline, upfront, milestone and royalty data  
  •  Comprehensive access to over 50 actual motor neurone disease deals entered into by the world’s biopharma companies since 2009  
  •  Insight into key deal terms included in contracts, where disclosed  
  •  Understand the key deal terms companies have agreed in deals  
  •  Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

 

 Executive Summary 

 Chapter 1 – Introduction 

 Chapter 2 – Trends in motor neurone disease partnering 

 2.1. Introduction  

 2.2. Motor neurone disease partnering over the years  

 2.3. Bigpharma motor neurone disease dealmaking activity  

 2.4. Motor neurone disease partnering by deal type  

 2.5. Motor neurone disease partnering industry sector  

 2.6. Motor neurone disease partnering by stage of development  

 2.7. Motor neurone disease partnering by technology type  

 2.8. Disclosed financial deal terms for motor neurone disease partnering  

 2.8.1 Motor neurone disease headline values  

 2.8.2 Motor neurone disease upfront payments  

 2.8.3 Motor neurone disease milestone payments  

 2.8.4 Motor neurone disease royalty rates  

 Chapter 3 – Leading motor neurone disease deals 

 3.1. Introduction  

 3.2. Top motor neurone disease deals by value  

 3.3. Top motor neurone disease deals involving bigpharma  

 Chapter 4 – Dealmaking directory 

 4.1. Introduction  

 4.2. Company A-Z  

 4.3. By deal type  

 

  •  Asset purchase  
  •  Bigpharma outlicensing  
  •  Co-development  
  •  Collaborative R&D  
  •  Co-market  
  •  Contract service  
  •  Co-promotion  
  •  CRADA  
  •  Cross-licensing  
  •  Development  
  •  Distribution  
  •  Equity purchase  
  •  Evaluation  
  •  Grant  
  •  Joint venture  
  •  Licensing  
  •  Manufacturing  
  •  Marketing  
  •  Option  
  •  Promotion  
  •  Research  
  •  Settlement  
  •  Spin out  
  •  Sub-license  
  •  Supply  
  •  Termination  

 

 4.4. By industry sector  

 

  •  Academic  
  •  Bigpharma  
  •  Biotech  
  •  Drug delivery  
  •  Medical device  
  •  Diagnostic  
  •  Generic pharma  
  •  Government  
  •  Non-profit  
  •  Pharmaceutical  
  •  Research tools  
  •  Services  
  •  Specialty pharma  

 

 4.5. By stage of development  

 

  •  Discovery  
  •  Pre-clinical  
  •  Phase I  
  •  Phase II  
  •  Phase III  
  •  Registration  
  •  Marketed  

 

 4.6. By technology type  

 

  •  Analysis  
  •  Animal models  
  •  Assays  
  •  Bioinformatics  
  •  Biological compounds  
  •  Biomarkers  
  •  Biomaterials  
  •  Cell culture  
  •  Cell therapy  
  •  Clinical testing  
  •  Diagnostic - companion  
  •  Devices  
  •  Diagnostics  
  •  Discovery tools  
  •  DNA probes  
  •  Drug delivery  
  •  Enabling technology  
  •  Epigenetics  
  •  Equipment  
  •  Facilities  
  •  Gene therapy  
  •  Genomics  
  •  Imaging  
  •  Industrial chemicals  
  •  In vitro models  
  •  Monoclonal antibodies  
  •  Nanotechnology  
  •  Oligonucleotide  
  •  Peptides  
  •  Personalised medicine  
  •  Processes  
  •  Proteomics  
  •  Radio/Chemo-therapy  
  •  Recombinant DNA  
  •  Research services  
  •  Research supplies  
  •  RNA therapeutics  
  •  Screening  
  •  Small molecules  
  •  Stem cells  
  •  Vaccines  

 

 Chapter 5 – Partnering resource center 

 5.1. Online partnering  

 5.2. Partnering events  

 5.3. Further reading on dealmaking  

 Appendices 

 Appendix 1 – Deal type definitions  

 About Wildwood Ventures  

 Current Partnering  

 Current Agreements  

 Recent titles from CurrentPartnering  

 Order Form – Reports  

 TABLE OF FIGURES 

 Figure 1: Motor neurone disease partnering since 2009  

 Figure 2: Bigpharma – top 50 –motor neurone disease deals 2009 to 2011  

 Figure 3: Bigpharma motor neurone disease deal frequency – 2009 to 2011  

 Figure 4: Motor neurone disease partnering by deal type since 2009  

 Figure 5: Motor neurone disease partnering by industry sector since 2009  

 Figure 6: Motor neurone disease partnering by stage of development since 2009  

 Figure 7: Motor neurone disease partnering by technology type since 2009  

 Figure 8: Motor neurone disease deals with a headline value  

 Figure 9: Motor neurone disease deals with upfront payment values  

 Figure 10: Motor neurone disease deals with milestone payments  

 Figure 11: Motor neurone disease deals with royalty rates, %  

 Figure 12: Top motor neurone disease deals by value since 2009  

 Figure 13: Top motor neurone disease deals signed by bigpharma value since 2009  

 Figure 14: Online partnering resources  

 Figure 15: Forthcoming partnering events  

 Figure 16: Deal type definitions